๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Esophageal Neoplasms
Clinical trial register · China

Esophageal Neoplasms Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 6 Beijing 4 Hangzhou 4 Nanchang 3 Fuzhou 3
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai6 Beijing4 Hangzhou4 Nanchang3 Fuzhou3
All 12 locations
Target enrolment
to

Esophageal Neoplasms trials in China

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer
NCT07745322Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
Peking University Cancer Hospital & Institute
Observational
270
Beijing
2026-05-20
Not yet open
A Clinical Study on the Effect of Massaging Tian Tu Acupoint on Coughing After Esophageal Surgery
NCT07518680Esophageal Neoplasms
Shanghai Zhongshan Hospital
Not applicable
30
Shanghai
2026-04-10
Recruiting
Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer
NCT07272382Esophageal Neoplasms
Fudan University
Not applicable
142
Shanghai
2025-06-05
Not yet open
Tranilast Vs. Steroids to Prevent Esophageal Stricture (TAPES) After Endoscopic Resection for Superficial Neoplasms
NCT06643689Esophageal Stricture, Esophageal Neoplasms
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
394
Hangzhou, Shaoxing
2025-01-01
Recruiting
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT06469944Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Merck Sharp & Dohme LLC
Phase 1/2
160
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, รœrรผmqi, Hangzhou
2024-09-20
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Merck Sharp & Dohme LLC
Phase 1/2
210
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, รœrรผmqi, Hangzhou
2024-08-07
Recruiting
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
NCT06646588Esophageal Neoplasms
Hebei Medical University Fourth Hospital
Phase 2
67
Shijiazhuang
2024-04-01
Recruiting
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
NCT06086457Esophageal Neoplasms
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
436
Beijing
2024-02-04
Recruiting
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
NCT05624099Esophageal Neoplasms, Esophageal Diseases, Digestive System Neoplasms
Fujian Cancer Hospital
Phase 2
75
Fuzhou
2023-08-01
Recruiting
Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
NCT05252078Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Esophageal Diseases, Gastrointestinal Neoplasms
Jiangxi Provincial Cancer Hospital
Phase 2
30
Nanchang
2022-06-02
Recruiting
Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer
NCT05800054Esophageal Neoplasms, Adverse Drug Event
The First Affiliated Hospital with Nanjing Medical University
Not applicable
210
Nanjing
2021-01-01
Active, closed
Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy
NCT04513418Esophageal Neoplasms
Hecheng Li M.D., Ph.D
Phase 3
244
Shanghai, Hangzhou, Ningbo
2020-11-10
Recruiting
Distribution of Lymph Node Metastases in Esophageal Carcinoma
NCT03222895Esophageal Neoplasms, Lymph Node Metastases
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Observational
5,000
Shanghai
2019-03-01
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/esophageal-neoplasms

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies listing the condition Esophageal Neoplasms.

How many Esophageal Neoplasms trials are recruiting in China?

9 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Esophageal Neoplasms), 13 studies
PhaseStudiesRecruitingShare
Phase 24330.8%
Not applicable3223.1%
Observational2115.4%
Phase 1/22215.4%
Phase 32115.4%

Most active sponsors

Lead sponsors with the most studies (Esophageal Neoplasms)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC22
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)11
Cancer Institute and Hospital, Chinese Academy of Medical Sciences11
Fudan University11
Fujian Cancer Hospital11
Hebei Medical University Fourth Hospital11
Hecheng Li M.D., Ph.D10
Jiangxi Provincial Cancer Hospital11
Peking University Cancer Hospital & Institute10
Second Affiliated Hospital, Zhejiang University, School of Medicine10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.